` LPTX (Leap Therapeutics Inc) vs S&P 500 Comparison - Alpha Spread

LPTX
vs
S&P 500

Over the past 12 months, LPTX has underperformed S&P 500, delivering a return of -80% compared to the S&P 500's 9% growth.

Stocks Performance
LPTX vs S&P 500

Loading
LPTX
S&P 500
Add Stock
www.alphaspread.com

Performance Gap
LPTX vs S&P 500

Loading
LPTX
S&P 500
Difference
www.alphaspread.com

Performance By Year
LPTX vs S&P 500

Loading
LPTX
S&P 500
Add Stock

Competitors Performance
Leap Therapeutics Inc vs Peers

S&P 500
LPTX
ABBV
AMGN
GILD
VRTX
Add Stock

Leap Therapeutics Inc
Glance View

Market Cap
16.2m USD
Industry
Biotechnology

Leap Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing novel therapies designed to treat patients with cancer. The company is headquartered in Cambridge, Massachusetts and currently employs 36 full-time employees. The company went IPO on 2017-01-24. The firm is focused on developing therapies designed to treat patients with cancer by inhibiting fundamental tumor-promoting pathways and by harnessing the immune system to attack cancer cells. The Company’s clinical stage program is DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1 (DKK1). DKK1 is a protein that regulates the Wnt signaling pathways and enables tumor cells to proliferate and spread, as well as suppresses the immune system from attacking the tumor. When DKN-01 binds to DKK1, an anti-tumor effect can be generated. DKK1 is a cell secreted protein that research has found its role in embryonic development. DKN-01 is an affinity, neutralizing monoclonal antibody targeting DKK1. DKN-01 reduces free DKK1 levels and has demonstrated an anti-tumor effect in preclinical models.

LPTX Intrinsic Value
Not Available
Back to Top